Nxera Pharma
4565.TPharmaceutical
Filed as Sosei Group Corporation (2022-08–2024-03)
Financials · Consolidated
| Fiscal year ended | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 | 2020-12 |
|---|---|---|---|---|---|---|
| Revenue | ¥29.6bn | ¥28.8bn | ¥12.8bn | ¥15.6bn | ¥17.7bn | ¥8.8bn |
| Operating income | −¥8.5bn | −¥5.4bn | −¥9.5bn | ¥3.4bn | ¥3.8bn | — |
| Net income (owners) | −¥12.5bn | −¥4.8bn | −¥7.2bn | ¥382m | ¥1.0bn | ¥1.5bn |
| Total assets | ¥134.8bn | ¥151.5bn | ¥157.2bn | ¥99.4bn | ¥97.0bn | ¥76.5bn |
| Net assets / equity | ¥61.0bn | ¥68.5bn | ¥66.8bn | ¥57.9bn | ¥57.5bn | ¥52.4bn |
| Operating cash flow | −¥2.7bn | −¥7.7bn | −¥5.3bn | ¥10.0bn | ¥7.1bn | ¥4.7bn |
| EPS (basic) | ¥-138.8 | ¥-53.92 | ¥-87.18 | ¥4.68 | ¥12.53 | ¥18.77 |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 13
| Period | Form | Figures |
|---|---|---|
| 2026-01-01 → 2026-06-30 | Half-year | 80 figures · EDINET |
| 2025-01-01 → 2025-12-31 | Annual | 196 figures · EDINET |
| 2025-01-01 → 2025-06-30 | Half-year | 80 figures · EDINET |
| 2024-01-01 → 2024-12-31 | Annual | 196 figures · EDINET |
| 2024-01-01 → 2024-06-30 | Half-year | 102 figures · EDINET |
| 2024-01-01 → 2024-03-31 | Quarterly Q1 | 80 figures · EDINET |
| 2023-01-01 → 2023-12-31 | Annual | 194 figures · EDINET |
| 2023-01-01 → 2023-09-30 | Quarterly Q3 | 102 figures · EDINET |
| 2023-01-01 → 2023-06-30 | Quarterly Q2 | 102 figures · EDINET |
| 2023-01-01 → 2023-03-31 | Quarterly Q1 | 80 figures · EDINET |
| 2022-01-01 → 2022-12-31 | Annual | 194 figures · EDINET |
| 2022-01-01 → 2022-09-30 | Quarterly Q3 | 102 figures · EDINET |
| 2022-01-01 → 2022-06-30 | Quarterly Q2 | 102 figures · EDINET |
32 more reports are still being processed.